Emerging role of lipid metabolism alterations in Cancer stem cells

Table 1 Inhibitors of lipid enzymes involved in CSCS

Metabolism type	Drug	Targeting enzyme	Cancer type	Stage
Lipogenesis	Resveratrol	FASN	Breast cancer CSCs [104, 209]. Glioblastoma CSCs [210, 231]. Pancreatic CSCs [232]	Clinical Trial
	Cerulenin	FASN	Glioma CSCs [103], Pancreatic CSCs [91]	Pre-clinical
	Orlistat	FASN	NSCLC [203]	FDA-approved anti-obesity drug
Lipid uptake	CD36 antibody	CD36	OSCC [126]	Pre-clinical
Lipid uptake	MTN	CD36	Glioblastoma CSCs [125]	Pre-clinical
FAO	Etomoxir	CPT1A	MYC-overexpressing TNBC [129], leukemia [219, 220]	Pre-clinical
FAO	ST1326	CPT1A	Lymphoma [170], acute myeloid leukemia [221]	Pre-clinical
Lipid desaturation	SSI-4	SCD1	Liver CSCs [176],	Pre-clinical
	BetA	SCD1	CRC [184]	Pre-clinical
	PluriSin#1	SCD1	Teratomas [148]	Pre-clinical
	MF-438	SCD1	Lung cancer CSCs [177]	Pre-clinical
	A939572	SCD1	CRC [185], clear cell renal cell carcinoma [233]	Pre-clinical
	Cay10566	SCD1	Breast Carcinoma [216]	Pre-clinical
	T-3764518	SCD1	CRC [234]	Pre-clinical

OSCC oral squamous cell carcinomas, CRC colorectal cancer, TNBC triple-negative breast cancer, MTN 2-methylthio-1,4-naphthoquinone, FAO fatty acid β-oxidation

ISSN: 1756-9966